Skip to content
Awesome – Lifestyle
Author:
Tango Therapeutics, Inc.; Erasca, Inc.
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
November 4, 2026